Asciminib: a new therapeutic option in chronic-phase CML with treatment failure
David T Yeung, Naranie Shanmuganathan, Timothy P. Hughes
Abstract
Asciminib, a first-in-class allosteric inhibitor of BCR::ABL1 kinase activity, is now approved for the treatment of patients with chronic-phase chronic myeloid leukemia who failed 2 lines of therapy or in patients with the T315I mutation. Promising attributes include high specificity and potency against BCR::ABL1, activity against most kinase domain mutations, and potential for combination therapy with ATP-competitive tyrosine kinase inhibitors. Clinicians now have expanded third-line options, which in most cases will involve a choice between asciminib and ponatinib.
Topics & Concepts
PonatinibMyeloid leukemiaMedicineTyrosine kinaseNilotinibDasatinibProtein kinase domainTyrosine-kinase inhibitorImatinibPharmacologyCancer researchOncologyInternal medicineBiologyMutantGeneticsCancerReceptorGeneChronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia ResearchAcute Myeloid Leukemia Research